TARSUS PHARMACEUTICALS, INC. Interest Income (Expense), Nonoperating, Net
TARSUS PHARMACEUTICALS, INC. (TARS) reported Interest Income (Expense), Nonoperating, Net of $10.34 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2024-02-27
- TARSUS PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for the quarter ending 2022-06-30 was -$247.00K, a 3628.57% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for the quarter ending 2022-03-31 was -$316.00K, a 3611.11% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for the quarter ending 2021-12-31 was $12.00K, a 20.00% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for the quarter ending 2021-09-30 was $8.00K, a 100.00% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for fiscal 2023 was $10.34M, a 195.43% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for fiscal 2022 was $3.50M, a 9619.44% increase from fiscal 2021.
- TARSUS PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for fiscal 2021 was $36.00K, a 80.85% decline from fiscal 2020.
- TARSUS PHARMACEUTICALS, INC. interest income (expense), nonoperating, net for fiscal 2020 was $188.00K.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 6 month | Interest Income (Expense), Nonoperating, Net 9 month | Interest Income (Expense), Nonoperating, Net 12 month |
|---|---|---|---|---|
| 2023-12-31 | $10.34M 10-K · filed 2024-02-27 | |||
| 2022-12-31 | $3.50M 10-K · filed 2024-02-27 | |||
| 2022-06-30 | -$247.00K 10-Q · filed 2022-08-11 | -$563.00K 10-Q · filed 2022-08-11 | -$551.00K derived: sum of 3 quarters · filed 2023-03-17 | -$543.00K derived: sum of 4 quarters · filed 2023-03-17 |
| 2022-03-31 | -$316.00K 10-Q · filed 2022-05-11 | -$304.00K derived: sum of 2 quarters · filed 2023-03-17 | -$296.00K derived: sum of 3 quarters · filed 2023-03-17 | -$289.00K derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $20.00K derived: sum of 2 quarters · filed 2023-03-17 | $27.00K derived: sum of 3 quarters · filed 2023-03-17 | $36.00K 10-K · filed 2023-03-17 |
| 2021-09-30 | $8.00K 10-Q · filed 2021-11-10 | $15.00K derived: sum of 2 quarters · filed 2022-08-11 | $24.00K 10-Q · filed 2021-11-10 | $34.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-06-30 | $7.00K 10-Q · filed 2022-08-11 | $16.00K 10-Q · filed 2022-08-11 | $26.00K derived: sum of 3 quarters · filed 2022-08-11 | $30.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $9.00K 10-Q · filed 2022-05-11 | $19.00K derived: sum of 2 quarters · filed 2022-05-11 | $23.00K derived: sum of 3 quarters · filed 2022-05-11 | $36.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $14.00K derived: sum of 2 quarters · filed 2022-03-14 | $27.00K derived: sum of 3 quarters · filed 2022-03-14 | $188.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $4.00K 10-Q · filed 2021-11-10 | $17.00K derived: sum of 2 quarters · filed 2021-11-10 | $178.00K 10-Q · filed 2021-11-10 | $154.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $13.00K 10-Q · filed 2021-08-05 | $174.00K 10-Q · filed 2021-08-05 | $150.00K derived: sum of 3 quarters · filed 2021-08-05 | $129.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $161.00K 10-Q · filed 2021-05-11 | $137.00K derived: sum of 2 quarters · filed 2021-05-11 | $116.00K derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$45.00K derived: sum of 2 quarters · filed 2021-03-31 | -$40.00K 10-K · filed 2021-03-31 | |
| 2019-09-30 | -$21.00K 10-Q · filed 2020-11-25 | -$16.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |